Evaluation of Pharmaceutical Care Program for Type 2 Diabetes Mellitus in Dhule
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 600
- 试验地点
- 2
- 主要终点
- Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded: Fasting blood glucose measurements recorded (mg/dl).Postprandial bloodglucoseRecorded
研究概览
简要总结
Evaluation of Pharmaceutical Care Program for Type 2 diabetes mellitus in Dhule
Objectives:-
- To evaluate Pharmaceutical care program in Type2 diabetics.
- To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.
- To study the prevalence of Type2 diabetics cases in Dhule.
- To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.
- To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.
- To study the impacts of Pharmaceutical care program on glycemic control in patients with Type-2 Diabetes Mellitus.
- To study the Drug utilization pattern in Type-2 Diabetes Mellitus in civil hospital Dhule.
- To compare the efficiency of Pharmaceutical care program and drug in patients with Type-2 Diabetes Mellitus.
- To study the Pharmaco-economic evaluation in Type-2 Diabetes Mellitus patient's.
- To increase the patient compliance and positive attitude of patients towards the diabetes disease by counseling.
详细描述
To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.
To study the prevalence of Type2 diabetics cases in Dhule. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.
To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria:
- •Patients with type 2 diabetes mellitus of either
- •Patients with HbA1c more than 7% and
- •Patients with blood sugar level more than 140 mg / dl
排除标准
- •Patient with end stage kidney disease.
- •Patient with heart failure.
- •Patient with chronic Diabetes problem and orthopedic problem
结局指标
主要结局
Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded: Fasting blood glucose measurements recorded (mg/dl).Postprandial bloodglucoseRecorded
时间窗: 24 weeks
Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded fasting blood glucose
次要结局
- Quality of Life score(24 weeks)
研究者
TABREJ MUJAWAR
tabrej mujawar mpharm Study principal investigator
R. C. Patel Institute of Pharmaceutical Education & Research